Latest Astellas Pharma Inc. Stories
HILDEN, Germany and TOKYO, October 28, 2014 /PRNewswire/ -- - First two programs aim to create tests to aid in cancer treatment with Astellas compounds
- AIMing to establish a new treatment for ophthalmologic diseases - TOKYO, Oct. 14, 2014 /PRNewswire/ -- Astellas Pharma Inc.
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept.
TOKYO, Aug. 8, 2014 /PRNewswire/ -- Cancer Research UK and its commercial arm, Cancer Research Technology ("CRT"), are to join forces with Astellas Pharma Inc.
Special Patient-Focused Event Kicks Off Astellas' Fifth Annual Changing Tomorrow Day Initiative KISSIMMEE, Fla., June 11, 2014 /PRNewswire/ -- About 1,400 Astellas Pharma employees
-Study appears in June 1 online edition- NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S.
LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Eight abstracts will highlight enzalutamide studies in prostate and breast cancers NORTHBROOK, Ill. and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S.
TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S.
NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.